JG
SRNE

Jefferies Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jefferies Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,524
Closed -$36.3K – 1874
2020
Q3 		$50K Buy
+4,524
New +$41.4K ﹤0.01% 1283
2019
Q1 		– Sell
-52,506
Closed -$126K – 2732
2018
Q4 		$126K Buy
52,506
+16,406
+45% +$53.6K ﹤0.01% 1931
2018
Q3 		$159K Buy
+36,100
New +$200K ﹤0.01% 2150
2018
Q2 		– Sell
-13,800
Closed -$71K – 2786
2018
Q1 		$71K Buy
+13,800
New +$98.2K ﹤0.01% 2101

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jefferies Group's SRNE Position: Q4 2020 in Review

Jefferies Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 4,524 shares — an estimated $36.3K sold.

Jefferies Group first reported a position in SRNE in Q1 2018 and held it in 4 quarters. The position peaked at $159K in Q3 2018. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Jefferies Group reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Jefferies Group sold 4,524 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $36.3K.
  • Jefferies Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
  • Jefferies Group's Sorrento Therapeutics, Inc. position peaked at $159K in Q3 2018.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Jefferies Group's 13F filing for Q4 2020, filed 16 Feb 2021.